• The agreement furthers Hovione´s ability to bring the benefits of continuous tableting, including reduced time to market and in...
Within3 and Array have announced a strategic partnership integrating synchronous and asynchronous insights management. This partnership is ...
The deal, valued at up to $1.05 billion, comprises an $800 million upfront payment and an additional $250 million contingent upon r...
Bayer and Aignostics GmbH, a pioneering force in computational pathology, have unveiled a landmark strategic partnership aimed at revolutionizing precision...
Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneous...
GMP material to be used in Phase Ib study in platinum-resistant ovarian cancer (PROC) patients scheduled to start this year. Previously reported Phase I sa...
Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce a strategic supply agreemen...
Global license and collaboration agreement set to advance the development of OSE-230, a monoclonal antibody aimed at resolving chronic inflammation. ...
Bristol Myers Squibb (NYSE: BMY) announced that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB). With the completion of the ...
Bitterroot Bio, a leader in innovative treatments for cardiovascular diseases, and Biotheus, a pioneer in monoclonal and multi-specific antibody design, an...
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimil...
Aleta Biotherapeutics (Aleta), a pioneer in immuno-oncology with a focus on CAR T-Cell Engager (CTE) platforms, in collaboration with Cancer Research UK&rs...
Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a prominent global biotechnology company specializing in advanced microbial platform...
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announces an antibody evaluation and option agreement with Gil...
© 2025 Biopharma Boardroom. All Rights Reserved.
